title: Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL).
authors.affiliation: Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.
authors.forename: N
authors.initials: N
authors.lastname: Shah
authors.affiliation: Department of Internal Medicine, West Virginia University, Morgantown, WV, USA.
authors.forename: S
authors.identifier: 0000-0002-0293-9527
authors.initials: S
authors.lastname: Rauenzahn
authors.affiliation: Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.
authors.forename: L
authors.initials: L
authors.lastname: Veltri
authors.affiliation: Department of Biostatistics, West Virginia University, Morgantown, WV, USA.
authors.forename: S
authors.initials: S
authors.lastname: Wen
authors.affiliation: Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.
authors.forename: M
authors.initials: M
authors.lastname: Craig
authors.affiliation: Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: M
authors.initials: M
authors.lastname: Hamadani
authors.affiliation: Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Kanate
authors.affiliation: Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.|Department of Pharmacy, West Virginia University Medicine, Morgantown, WV, USA.
authors.forename: A
authors.initials: A
authors.lastname: Cumpston
mesh_terms: D000328:Adult; D000368:Aged; D064592:Autografts; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013852:Thiotepa / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors
chemical_list: D013852:Thiotepa